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Abstract
Background: Traditional randomised controlled trials evaluating the effect of educational interventions in general
practice may produce biased results as participants know they are being evaluated. We aimed to explore the
acceptability of a McNulty-Zelen Cluster Randomised Control Trial (CRT) design which conceals from educational
participants that they are in a RCT. Consent is obtained from a trusted third party considered appropriate to give
consent on participants’ behalf, intervention practice staff then choose whether to attend the offered education as
would occur with normal continuing professional development.
Methods: We undertook semi structured telephone interviews in England with 16 general practice (GP) staff involved
in a RCT evaluating an educational intervention aimed at increasing chlamydia screening tests in general practice using
the McNulty-Zelen design, 4 Primary Care (PC) Research Network officers, 5 Primary Care Trust leads in Public or sexual
health, and one Research Ethics committee Chair. Interviews were undertaken by members of the original intervention
evaluation McNulty-Zelen design RCT study team. These experienced qualitative interviewers used an agreed
semi-structured interview schedule and were careful not to lead the participants. To further mitigate against
bias, the data analysis was undertaken by a researcher (CR) not involved in the original RCT.
Results: We reached data saturation and found five main themes;
Support for the design: All found the McNulty-Zelen design acceptable because they considered that it generated
more reliable evidence of the value of new educational interventions in real life GP settings.
Lack of familiarity with study design: The design was novel to all. GP staff likened the evaluation using the McNulty–Zelen
design to audit of their activities with feedback, which were to them a daily experience and therefore acceptable.
Ethical considerations: Research stakeholders considered the consent procedure should be very clear and that these trial
designs should go through at least a proportionate ethical review. GP staff were happy for the PCT leads to give consent
on their behalf.
GP research capacity and trial participation: GP staff considered the design increased generalisability, as staff who
would not normally volunteer to participate in research due to perceived time constraints and paperwork
might do so.
Design ‘worth it’: All interviewees agreed that the advantages of the “more accurate” or “truer” results and
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information gained about uptake of workshops within Primary Care Trusts (PCTs) outweighed any disadvantages of the
consent procedure.
Discussion: Our RCT was evaluating the effect of an educational intervention to increase chlamydia screening tests in
general practices where there was routine monitoring of testing rates; our participants may have been less enthusiastic
about the design if it had been evaluating a more controversial educational area, or if data monitoring was not routine.
Implications: The McNulty-Zelen design should be considered for the evaluation of educational interventions, but these
designs should have clear consent protocols and proportionate ethical review.
Trial registration: The trial was registered on the UK Clinical Research Network Study Portfolio database. UKCRN9722.
Keywords: Education for Health Care Professionals, Clinical trials (epidemiology), Public Health Ethics, Primary
Care, Ethics, Screening
Background
The method used to select participants within a Ran-
domised Controlled Trial (RCT) is a crucial aspect of
trial design [1]. In a traditional RCT, individuals are
the unit of analysis and are invited to participate and
consent; it is at this point randomisation to an inter-
vention occurs. In a standard cluster randomised trial
groups of participants (“clusters”), rather than individ-
uals, are invited to participate and consent to take
part before randomisation. The consent procedure
can lead to loss of eligible clusters, because of low re-
cruitment [2, 3].
Selection of only a subgroup of possible participants
will affect external validity of a trial; that is the trial’s
generalizability (applicability) and relevance to clinical
or public health practice [4]. Random assignment to an
intervention is considered the gold standard and when
properly implemented it eliminates selection bias. Pro-
ducing unbiased results is particularly challenging in
educational interventions involving healthcare staff, as
staff in research networks who are the most common
participants in research may not be typical, and health
care staff interested in the education content are
more likely to volunteer. Furthermore, staff who know
they are part of an educational evaluation may try
harder to change any behaviour they know is being
measured [5]. To help overcome these challenges, we
recently used a modified Zelen Cluster Randomised
Controlled Trial design to evaluate a complex educa-
tional intervention aimed at increasing chlamydia
screening tests in English general practices [6] (Fig. 1).
There are several types of the Zelen design [7]. In the
double consent Zelen design all potential participants
are first randomised and are then asked to consent;
intervention participants can refuse to be involved
completely or choose to move over to the control
arm. In the single consent Zelen design all partici-
pants are randomised to intervention or control, but
consent is only sought from the intervention group
[8]; the control group receive standard care, and do
not know about the intervention or the trial [7]. In
our modified Zelen consent variant for educational
intervention evaluations, all potential participants are
randomised but no consent is obtained from interven-
tion or control groups. Instead consent is obtained
from a trusted third party considered appropriate to
give consent on participants’ behalf, and then inter-
vention practice staff can choose whether to attend
the offered education. This consent is usually ob-
tained before randomisation, so that researchers do
not collect any unnecessary information about prac-
tices and their staff who will not be involved. The au-
thors have chosen to call this new modified design
the McNulty-Zelen design to differentiate it from
other modified Zelen designs. As far as we know this
McNulty-Zelen Design has only been used by our
group [6, 9], and a recent editorial critiquing the
study questioned “was that deception necessary?” [10]
Neither its acceptability, nor that of the Zelen Design,
has been evaluated with participants involved in such
a study.
We aimed to explore the views of our trial partici-
pants, and other stakeholders involved in primary
What this paper adds
What is already known on this subject:
Studies have found that Zelen designs increase external and internal
validity, but there has been little research into their acceptability with
participants who have been involved in Zelen design studies.
What this study adds:
The study suggests that the McNulty-Zelen design, in which participants
are unaware of their participation in a trial where consent is given by a
trusted third party, is acceptable to both stakeholders and GP staff
in primary care for the evaluation of educational interventions. The
McNulty-Zelen design is a promising addition to trial designs for
the evaluation of educational interventions; the role of the trusted
third party giving consent needs to be clearly defined.
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care research, about the acceptability of the McNulty-
Zelen design for evaluation of educational interven-
tions. We used the chlamydia RCT as an exemplar.
Methods
RCT design
Our RCT using the McNulty-Zelen Design has been pre-
viously described [6]. Briefly, 160 general practices were
block randomised to the intervention or control. Interven-
tion practices were offered an educational outreach work-
shop and two further contacts with a chlamydia support
worker. The RCT design was discussed and approved by
the Warwickshire Research Ethics Committee (REC Ref:
08/H1211/57) and locally approved by Primary Care trusts
(PCTs). Informed consent for practice involvement was
sought from the Public Health or sexual health leads
within each PCT.
The educational intervention took place between April
2010 and April 2011, and in December 2011, after process
evaluation interviews had been completed, all randomised
surgeries were sent a letter to let them know that their
practice had been taking part in a RCT of an intervention
aimed at increasing chlamydia screening in general practice,
and providing information about their random allocation,
the consent procedure, the reason for the trial design and
references explaining the Zelen design [7] Additional file 1.
Qualitative interviews
The interviews were approved in a substantial amend-
ment (May 2011; REC Ref: 08/H1211/167) to the
original RCT trial through the Ethics Committee. The
qualitative interviews took place between December
2011 and June 2012, 1–6 months after the explanatory
letters and one year after intervention completion, but
before any publication of trial results.
Participant selection
GP staff
To reduce work overload for the GP staff and any repeti-
tion effects arising from being interviewed on two separ-
ate occasions, we excluded intervention practices that
had taken part in previous process evaluation interviews;
these excluded practices did not differ in any way from
the Zelen interview practices in terms of practice list
size, chlamydia screening rates, deprivation, or training
doctors in the practice. The intervention (whether they
agreed to workshops or not) and control surgeries were
approached in random order. In each selected practice
we invited the clinical lead for research or training to
participate in the interviews, or to nominate an appro-
priate individual to participate. From previous experi-
ence of time taken to reach data saturation, we aimed to
recruit up to 16 GP practice staff.
Other stakeholders
We used maximum variation sampling and purposively
invited a range of stakeholders involved in coordinating
research in Primary Care Research Networks (PCRNs),
PCT leads in similar positions to those who were in-
volved in giving consent for our research, and members
Fig. 1 Randomisation and consent with McNulty-Zelen design and usual cluster RCT; detailed legend, comparative processes for traditional cluster
RCT and the McNulty-Zelen design used in this study
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of research ethics committee to participate. We aimed to
interview ten stakeholders.
All potential participants were approached by tele-
phone and those interested in participating were asked
to give informed consent by post or email. Participants
were not offered any financial incentives.
Interview schedule
A semi-structured interview schedule (Additional files 2
and 3) was developed for the telephone interviews by
the research team. To ensure understanding of the de-
sign, at the start of each interview the researchers gave
an oral explanation of the McNulty-Zelen design. The
interview schedule then explored using open questions
and probing: participants’ thoughts on the benefits and
disadvantages of the design, the ethics procedure, how
involvement in a traditional RCT design may have influ-
enced their participation or behaviour, and whether use
of McNulty-Zelen designs should be encouraged. If par-
ticipants did not understand the McNulty-Zelen design,
this was explained to them in a factual way so that they
could answer the later questions on the advantages and
disadvantages of the design. GP staff in control or inter-
vention groups were also asked hypothetical questions
about their reactions if they had been in the other group,
and if they were asked to consent to participate in the
RCT. Interviewers were careful to ensure that the partic-
ipants fully understood the question, and gave further
explanation where needed. The stakeholders were also
asked about the new National Research Ethics Service
(NRES) procedures from 2011, which no longer requires
ethical approval for research that only involves NHS staff
[11]. GP staff were not asked these questions, as their in-
terviews took place before the study group was aware of
the planned change in regulations, and it was not con-
sidered appropriate to re-interview them.
Interview procedure
Three researchers undertook telephone interviews (ER,
CMCN, EO). The interviewers were part of the original
RCT team, but did not interview staff they had trained
or knew. Furthermore they were trained in qualitative
interviewing techniques (through courses and experi-
ence). To prevent bias in data collection, interviewers
reflected on their interview technique, feelings, reactions
and biases during interviews. They then discussed this
with other interviewers and the wider research team to
optimise their interviewing technique. One pilot inter-
view with a nurse, from one of the randomly selected
practices, informed minor changes to the interview
schedules. As data collection progressed, interviewers
met together and with the wider research team to dis-
cuss the emerging themes noted after the interviews, to
check if further probing questions were needed and
when data saturation had occurred. After about twelve
interviews findings were very consistent, and we there-
fore stopped interviews after completing 16. The formal
data analysis below using NVivo was undertaken by one
researcher after all data collection was complete. Inter-
views lasted 15 to 25 min, were recorded digitally, tran-
scribed verbatim by a research assistant (EO) and cross
checked by two further researchers (CR and ER) who
checked the transcripts while listening to the recordings.
Data analysis
Data were anonymised. CR, who was not involved in the
RCT, undertook comprehensive analysis of all transcripts.
A six-stage Thematic Analysis using an inductive ap-
proach was used by the three researchers coding data (CR,
CMCN, ER) [12] Additional file 4. 1) Familiarising yourself
with the data: First initial notes and ideas were recorded
by CR, listening to the audio of each interview when read-
ing and rereading the transcripts. 2) Generating initial
codes: QSR NVivo 10 was then used to comb the data line
by line for themes, ideas, concepts, terms, phrases and cat-
egories, and descriptive codes were generated [13]. 3)
Searching for themes: Similarly coded data were collated
together and initial ideas were mapped on to thematic
models. Researchers analysed answers to the hypothetical
questions about their behaviour if they had been in the
other arm of the RCT carefully making sure that the par-
ticipants fully understood the scenario being described. 4)
Reviewing themes: two other researchers (ER and CMCN)
read and coded 20 % of the transcripts and the codes gen-
erated by the additional researchers were reviewed and
discussed by three authors (CR, ER, CMcN); there were
no significant disagreements about the themes. 5) Defin-
ing and naming themes: names for each theme were then
agreed and CR revisited the data refining themes. Using
the full data set and discussions CR made a Thematic
Map. In the thematic map arrows indicate where respon-
dents made links between the themes. Data extracts were
selected to illustrate these main thematic findings [12]. 6)
Producing the report: the final report was written.
Results
All practices involved in the original RCT were invited
to contact the project manager with any concerns fol-
lowing the information letter sent to them about their
random allocation, the consent procedure, the reason
for the trial design and references explaining the Zelen
design, but none did so.
Twenty four of 27 GP practices approached gave ver-
bal approval for interviews. Three practices indicated
they did not have time to participate. Eighteen inter-
views were arranged and written consent was sought.
One participant withdrew and one refused consent for
transcription. Sixteen interviews were analysed from ten
McNulty et al. BMC Family Practice  (2015) 16:169 Page 4 of 11
Fig. 2 Recruitment of GP staff for interviews; detailed legend, Flowchart depicting process of recruitment of GP staff for interviews
Fig. 3 Thematic Map of Main Themes found in qualitative interviews; detailed legend, Map of 5 themes from Thematic Analysis of all interviews
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intervention practices (6 who agreed to workshops and
4 who did not; 4 Nurses, 3 GPs, 3 practice managers)
and six control practices (3 nurses, 2 GPs, 1 practice
manager). Ten of 12 stakeholders approached agreed to
participate (4 PCRN officers, 5 PCT leads in Public or
sexual health, and a Chair of a Research Ethics commit-
tee) (Fig. 2). Initial analysis conducted as interviews were
ongoing indicated that data saturation was reached.
Later interviews and full analysis of all interviews con-
firmed this.
The thematic map illustrates how four themes of ini-
tial lack of familiarity with the design, ethical consider-
ations, the design being worth it, and GP research
capacity feed in to the final theme; overall support for
the McNulty-Zelen design consent procedure (Fig. 3).
Lack of familiarity with the study design; Table 1:
The theme of lack of familiarity was a fundamental part
of the interview results, and none of the GP staff partici-
pants reported that they had heard of it prior to receiv-
ing information about it from the researchers, several
needed reminding at the interview.
Trial design seen as feedback and monitoring: The par-
ticipants, particularly the GP staff, considered the trial
design was similar to the way their activities were moni-
tored, and fed back to them by the PCT and others. As
GP staff felt their daily work often involved meeting tar-
gets this was a familiar concept and made the design
very acceptable to them.
Support for the consent procedure; Table 2: Most in-
terviewees found the consent procedure acceptable; all
GP staff interviewed felt it was appropriate. None of the
interviewees saw the need for additional people to be in-
volved in the consent procedure. Any concerns with the
consent procedure were about ensuring that an appro-
priate person was given the responsibility of consenting,
rather than about the actual Zelen design or consent
procedure itself. The concerns came from five of the
stakeholders (none of the GP staff ) who were in roles
that had been involved in consenting on behalf of prac-
tices, but had not actually been involved in the consent
procedure as their predecessor had given consent. These
stakeholders questioned whether their role as Directors
of Public Health gave them the right to consent on be-
half of ‘independent GP practices.’ They wanted to see a
clear procedure to choose those who gave consent. The
one stakeholder who was involved in the consent pro-
cedure did not report any issues with the consent. Some
stakeholders were worried that the consent procedure
may damage relationships between PCTs and GPs (see
next theme) and therefore this needed to be treated sen-
sitively. Some interviewees (5 GP staff and 5 stake-
holders) speculated that others, rather than themselves,
might be apprehensive about this procedure. Others
stated that as only anonymised data were collected this
made the consent procedure acceptable. GP staff also
felt that further written consent from GP practices was
unnecessary as both practice managers and GP staff had
the choice not to attend the educational workshops, and
could refuse any further visits or contacts by the chla-
mydia coordinator, and they also knew their chlamydia
testing rates were already being monitored. The fact that
practices and staff in the original trial had to opt in to
education was implicitly interpreted as “tacit consent”.
However this could not be said for control practices.
None of the interviewees saw the need for additional
people to be involved in the consent procedure.
Ethical Considerations; Table 3: The ethical implica-
tions of the study were discussed in detail by
participants.
Awareness of trial influences behaviour: All partici-
pants reported that they viewed the trial design as ap-
propriate because awareness of participation in the trial
could have of itself influenced their own or others be-
haviour, which could have biased the trial findings. This
was seen as part of human nature, and as such some-
thing that could not be avoided, unless the McNulty-
Zelen or similar design was used. Some participants
noted that the problems associated with this lack of indi-
vidual informed consent needed to be balanced with bias
caused by awareness of the trial. 14 interviewees, both
Table 1 Lack of familiarity with the study design
Lack of familiarity with the design:
Z8, NURSE: “I was unsure of what the design was having not heard
about the Zelen design before and never been involved in a project that
incorporated this type of auditing”
Z13, GP: “I was quite fascinated by it …whether I truly understand it I
don’t know but er it’s intriguing”
S1, PCRN SENIOR RESEARCH OFFICER: “initially I thought well that’s
something different because obviously normally we would seek interest
from the practice and get their consent initially before they took part in
a study so this was obviously the opposite way of approaching it. But
then reading through it why it was a good way”
Trial design seen as monitoring of performance:
Z13, GP: “I go into this assuming something like this is going to
happen going to look at your figures PCT’s are always looking at your
figures”
Z14, GP: “monitoring of our performance is just sort of second nature”
Table 2 Support for the consent procedure
S3, PUBLIC HEALTH MANAGER AND SEXUAL HEALTH LEAD: “I don’t
see any issue with the consent process that you followed”
S10, PCRN SENIOR RESEARCH OFFICER: “because the data is already
there then what you’re doing is scrutinising that and looking at to see
whether the level of that data collection has been the quality and levels
have increased after the intervention so in that sense I guess it’s less.. of
a problem”
Z6 “I can see the rationale behind it [Zelen design] and that sounds
good.”
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stakeholders and GP staff stressed the importance of
informing participants about the design after trial com-
pletion, and spoke positively about the explanatory letter
about the design researchers had sent to each practice,
seeing this as an important part of transparency and
trust in the ethical procedure.
PCT GP Relationships: Some GPs felt that the relation-
ships between certain PCTs and General Practices were
not good, but none had concerns about the PCT sexual
health leads consenting on their behalf. In contrast, al-
though the PCRN and PCT stakeholders were happy
that the process was ethical, five of the stakeholders
were worried that the consent procedure may damage
already fragile relationships between GP staff and PCTs.
Their anxiety was that GP staff would be offended or
upset that PCTs had consented on their behalf, and pos-
sibly that GP staff would therefore feel they had not
been given a choice. The pre-existing issues between
them mentioned by GP staff and stakeholders were a
lack of trust and communication which may be exacer-
bated by the consent procedure.
Ethical approval important because of design: Most
stakeholders felt there was a need for some sort of eth-
ical approval being sought for this novel design; this was
additional to the PCT consent procedure and local ap-
provals that were in place for the trial. There was a
strong feeling from stakeholders that there should be a
nationally agreed ethical process for trials where consent
was not sought, even if the intervention only involved
health care staff. This was because of the novel design
and the unusual consent procedure that it entailed; some
suggested this could involve only a proportionate or
chairman’s review.
GP research capacity and trial participation; Table 4:
Most GP staff reported that their capacity to participate
in research was constrained because of time limitations.
Many said that if the trial had used a traditional design
and consent procedure the real and perceived extra time
and paperwork associated with research for them and
their practice might have dissuaded them from partici-
pating. They reported that the McNulty-Zelen design re-
duced this research paperwork and therefore allowed
more non-research practices to participate in the educa-
tional intervention evaluation, so increasing generalizability
of results.
Design as beneficial; ‘worth it’; Table 5: This theme
was alluded to in a number of ways by most participants.
The views expressed were generally that the benefits of
the study outweighed the disadvantages and made it
worthwhile. Most participants did not perceive there
being any disadvantages to using the McNulty-Zelen
design.
Table 4 GP research capacity and trial participation
Z14, GP: “There’s also kind of competing interests of a day to day job
that increasingly sort of jam packed. And with the best will in the world
you sometimes look at things already sent to them and think oh that
looks like a really useful thing to … fill in or contribute to. Actually you
may not actually get around to it,- so I suppose this is at least one way
of ensuring participation of the people you’re trying to look at”
Z2, PRACTICE MANAGER: “It is possible I’d have chuckled and said oh we
haven’t got time to do that because that is very much how that’s my
first thought is time. … I think the answer to that would have to be, it
depends and I’m sorry it’s not a clear answer but we make a decision at
this moment in time based on a whole kind of factors, so at the time
when we received the information we would have sat down and
decided whether that was the right thing for the practice.”
Z15, NURSE: “I might have said oh no not another trial, I haven’t got
time! But in actual fact it didn’t involve us doing anything did it?”
Z12, NURSE: “But whether or not the doctor would have agreed to it
would have been [the deciding thing] he more than likely discouraged it
because of time, and if he’d have to get involved personally would have
probably declined it because of his time”
Table 3 Ethical Considerations
Z2, PRACTICE MANAGER: “where we’re not notified in advance actually is
a really good idea it gives you a really true picture of the reality”
S6, ASSISTANT JOINT COMMISSIONING MANAGER: “I just think the
perception of some individuals may be that it’s slightly underhand”
Awareness of trial influences behaviour:
Z15, NURSE: “I think it’s a very good thing if you do research without
us knowing about it really because you’re getting a true life situation
aren’t you? Actually rather us thinking oh yes we really need to do that,
we’d better do that because we’re in a trial.” “Its natural reaction isn’t it
to think well we’re doing this therefore we’ve got to perform better at
this.”
Z10, GP: “you might feel obliged to increase your screening so I think
blindness is useful”
Z9, NURSE: “as far as consent for this goes …if somebody is taking
that out of our hands and doing it as a at a PCT level then that’s fine
but I think sometimes it’s nice to know that that an annual thing or an
on-going thing so we consenting that it’s going to happen but we don’t
necessarily need to know when it’s going to happen.”
PCT GP Relationships:
S4, PUBLIC HEALTH COMMISSIONING MANAGER - SEXUAL HEALTH: “I
worry quite a lot that we … are investing quite a lot of work in primary
care to make them see that we’re working together and that we can all
trust each other, and I just worry that they might get frustrated that
were kept out of that decision.”
Z9, NURSE: “Some people might always look on the bleak side, and
think you know are they trying to catch us out, you know what are they
trying to gain from it?”
Ethical approval important because of design:
S8, PCRN RESEARCH OFFICER: “Because it’s so novel it’s such a novel
design you do need something in place that will ensure GPs that the
research was ok so for this type of design. I would actually probably be
seeking the ethics for educational research.”
S1, PCRN SENIOR RESEARCH OFFICER: “Approval should still be sought
because I think there still needs to be some checks and balances on the
study design.”
S5, REC CHAIR: “I think it would be helpful if this sort of [Zelen] design
was at least shown to a chair to confirm or make everybody feel
comfortable that it really was the sort of Zelen design that could raise
no issues.”
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Gives a realistic picture and strong evidence: Almost
all participants talked about the trial design being bene-
ficial, as it gave a truer picture or more accurate result,
and therefore the evidence was stronger than in a RCT
involving research practices.
Less skewed selection of practices: That the trial design
produced a “less skewed” selection of practices taking
part because consent to participation was given by the
PCT and not just research practices were involved was
seen as an added benefit of this study.
Discussion
Main findings
All participants reported that they felt the McNulty-
Zelen design generated stronger and more reliable evi-
dence for the value of implementing a new intervention
in a real life setting. All GP staff participants and stake-
holders felt overall the consent process was acceptable
but some stakeholders queried the procedure for identi-
fying who should be responsible for giving consent on
behalf of the GP practices. As the design was so novel
and consent was not obtained directly, the stakeholders
from research networks and ethics committees suggested
that even if the intervention only involved NHS staff
these sort of trial designs should go through at least a
proportionate review by NRES. GP staff likened the
study design to audit and feedback which were common,
familiar and acceptable processes [14]. All GP staff re-
ported that as knowledge of the trial would have modi-
fied their chlamydia testing behaviour irrespective of
whether they were in an intervention or control practice,
the main advantage for the design was the production of
less biased results. Participants thought that a more
generalizable range of practices could offer to participate
because of the lower paperwork requirements of this de-
sign, and data could be collected on workshop participa-
tion rates.
Strengths and limitations
As far as we know this is the first study exploring the opin-
ions of GP staff or stakeholders actually involved in a Zelen
RCT. We consider our findings are transferable to other
studies evaluating Public Health or educational interven-
tions in Primary Care across England as we recruited a di-
verse sample of GP staff from a range of different GP
practices and stakeholders. We also interviewed both con-
trol and intervention practice staff (including staff in prac-
tices who were randomised to the intervention, but did not
agree to the chlamydia support worker led workshops).
One of the main reasons the participants found the design
so acceptable is because they likened the research to per-
formance auditing as they knew that data about their chla-
mydia screening rates was already being collected. Thus
the findings may not be as applicable to educational inter-
ventions where routine data is not being routinely collected
and monitored. The interviews were by financial necessity
undertaken by members of the RCT study team, and there-
fore this could have introduced some bias into data collec-
tion and probing. However the interviewers were as a
result familiar with the design and workshop and could
probe appropriately, furthermore the interviewers did not
deliver the intervention directly to any staff they inter-
viewed, did not know how active the participating surgeries
were at chlamydia screening, were experienced in qualita-
tive methods, used the agreed semi-structured interview
schedule and were careful not to lead the participants. To
further mitigate against bias, the data analysis (except for
some double coding) was undertaken by a researcher (CR)
who was not involved in the original RCT. We also
reached data saturation relatively quickly and later inter-
views served to confirm earlier results.
Interviews were undertaken by telephone, which aided
recruitment of busy GPs and stakeholders, but may have
reduced the flow of conversation and shortened the
Table 5 Design as beneficial; ‘worth it’
Z12, NURSE: “As long as there’s some useful information that comes
from it, I’ve got no personal objections to being part of trial that
somebody else has, that the PCT have agreed to.”
S5, REC CHAIR: “I happen to think that the benefits far, far outweigh any
of the disadvantages of this particular study”
S2, COMPREHENSIVE LOCAL RESEARCH NETWORK RESEARCH,
MANAGEMENT AND GOVERNANCE (RM&G) MANAGER: “They [GP staff]
can see reasons for it then I think that would probably justify it.”
Gives a realistic picture and strong evidence:
Z17, NURSE: “Because it doesn’t give you um a rose coloured view of
what’s going on it gives you the true picture.”
S4, PUBLIC HEALTH COMMISSIONING MANAGER - SEXUAL HEALTH:
“You should get just a pure result depending on the intervention, yes not
based on … any sort of self-selection or wanting to achieve, … a better
result because you are in a trial … so I think that is a huge advantage
of this [design].”
S6, ASSISTANT JOINT COMMISSIONING MANAGER: “I think … if people
don’t know that they’re involved then they carry on with their normal
behaviour regardless, and therefore arguably you get a truer picture of
.what they do and how they go about doing it, um without behaviour
modifications to conform to um any expectations from a study being
carried out.”
Z8, NURSE: “The audit is always going to be accurate and valid …
because we didn’t know what was going on and we were unaware that
we were being visited. I think the information gleaned can then be very
accurate.”
Less skewed selection of practices:
S1, PCRN SENIOR RESEARCH OFFICER: “Because if you did approach
the practice then obviously you get those that are interested in and
have a particular interest in chlamydia screening or who knew their
practice were quite good at, at doing what they’re supposed to be
doing, so it could skew the study result. Um so I think it was a good
way of um getting a sort of cross section of the practices really, rather
than just those who had a particular interest.”
Z6, GP: “It would have been an additional inconvenience if () asked
for consent”
McNulty et al. BMC Family Practice  (2015) 16:169 Page 8 of 11
interviews. We only interviewed one of the Public
Health leads who gave the original consent for the Zelen
design, as half had changed roles in the time since con-
sent was given in 2008. However we can surmise that
the other consenting individuals were happy with the de-
sign as it was discussed with them before they gave in-
formed consent, and none of the 16 area leads involved
in the original study refused consent.
Recall bias may have biased results as the interviews
were undertaken one to six months after letters explain-
ing the study were sent to practices. Some participants
reported lack of time to read the Zelen design informa-
tion sent before the interview. Thus to ensure under-
standing before the interview the researchers gave a
neutral, factual explanation of the design; this may have
limited the participants responses. This was countered
by probing with open questions.
The GP interviews were undertaken before the study
team knew that ethical approval would not be needed
for studies just involving NHS staff, and therefore did
not ask GP staff their views about the new regulations.
GP staff may have had a different view about the new
regulations, as they reported the importance of saving
time and concentrating on PCT priorities and were less
concerned about the consent procedure. We thought it
was important to report these stakeholder results as they
have important implications for future ethical approvals
of similar studies.
Where this research fits in
One qualitative study has explored with parents, whose
newborn infants had previously been enrolled in a com-
pleted conventional RCT, their views about a hypothet-
ical situation in which the Zelen design may have been
used to recruit their child to the same study [15]. Similar
to our GP staff, participants in Snowdon’s qualitative
study felt that they did not need to give consent for
anonymised data that is routinely collected to be moni-
tored [15]. This is also clearly stated in the UK Govern-
ance Arrangements [11]. Parents in Snowden’s
qualitative study also thought that the Zelen design may
undermine trust between the parent and health-care
staff [15]. The major disadvantage of Snowdon’s study is
that it was discussing a hypothetical study design [15].
Stakeholders in our study, who were also not directly in-
volved in the intervention, in a similar way thought that
the Zelen design may undermine trust between the PCT
(who gave consent) and GP staff. This was not men-
tioned as a disadvantage by any of the GP staff them-
selves, who reported being accustomed to PCTs
measuring their performance. In Snowdon’s work with
parents, knowledge of the outcomes of the study and
their involvement was important and gave participants a
sense of contributing to medicine [15]. This is consistent
with our findings as all interviewees supported the re-
search team informing the study participants about the
McNulty-Zelen study design and results, reporting that
this was an important component of the study design.
Improved recruitment
In a systematic review the consent procedure and in-
creased demands on clinician’s time during the research
period were the most commonly reported clinician re-
lated reasons for non-entry of eligible patients into sur-
gical RCTs [4]. Several of our interviewees reported that
they may not have participated in a research related edu-
cational intervention because of the perceived extra
time, clerical work and data collection expectations in
research studies. The use of the Zelen design has been
used to increase recruitment resulting in a 6-fold in-
crease in recruitment in an arthroscopy study [16]. Our
interviewees’ views agreed with a review of 44 studies
using the Zelen design [17], in which half stated that
they used the design to reduce bias, and is highlighted
by the less than 50 % recruitment in several other GP
educational cluster randomised trials [5, 18]. The
McNulty-Zelen design has the advantage of demon-
strating the real acceptance rate of an educational
intervention [6]. Our GP staff report that knowing they
were in a trial might make them “try harder”, is also
reflected in an educational study on respiratory tract
infections (RTI) in which the intervention GPs diag-
nosed significantly more RTIs than GPs in the control
arm [5].
We suggest that the McNulty-Zelen design and con-
sent process is similar to a cluster randomised trial, if
the PCT were considered the cluster and the GP prac-
tices the participants [3]. Within a cluster RCT the deci-
sion about whether a particular cluster participates in a
trial is taken by a “guardian” who usually has the power
to “deliver” that cluster [3]. Examples are chief executive
of a hospital, or the managing partner of a GP practice;
within the McNulty-Zelen design study consent was
taken one step further up from the GP’s involved and
was given by PCT Public Health or Sexual Health leads.
All the GP staff participants were happy with who gave
consent, and stakeholders were happy if the process of
identifying a suitable individual to consent was clearly
explained. Edwards et al. suggest that in cluster rando-
mised trials the guardians’ consent form should clearly
set out their duties [3]. We suggest a similar procedure
for McNulty-Zelen designs, as this may go some way to
allay the fears of stakeholders about the possible risk to
the GPs relationship with a service commissioner [19].
McRae et al. also discussed the ethics of lack of consent
in cluster randomised trials [20]. We would suggest that
the interviewees provided us with enough evidence to
indicate that the criteria in the United States Common
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Rule [21] governing research which permits a research
ethics committee to waive the requirements to obtain in-
formed consent were met. These are: (a) “The research
involves no more than minimal risk to the subjects” (our
education was unlikely to lead to any harm); (b) “The
waiver or alteration will not adversely affect the rights
and welfare of the subjects” (participants in our RCT
could refuse the education and only routinely collected
data was analysed [6]); (c) “The research could not prac-
ticably be carried out without the waiver or alteration”
(informing all practices about the intervention may have
reduced recruitment and increased bias [6]); and, (d)
“Whenever appropriate, the subjects will be provided
with additional pertinent information after participa-
tion” (practices were given information after the study
end) [6]. The NRES does not have similar clear criteria,
but does state that “there is evidence that a universal in-
sistence on consent can undermine research, introducing
bias and limiting recruitment” [22]. NRES goes on to say
that “the legal position is uncertain” and “expert advice
is needed on when it is appropriate to conduct research
without consent.”
Conclusions
While a few interviewees indicated the consent process
might reduce trust between GP staff and PCT leads, the
results indicate promise for the application of the
McNulty-Zelen design for the evaluation of educational
interventions where routine anonymised outcome data
can be collected, although application in other contexts
to examine the extent to which this support holds is
warranted. However, there are some provisos; primary
care stakeholders consider that to reduce any possibility
of loss of confidence in the ethical and local review
process this sort of study design should be subject to at
least proportionate ethical review by NRES. Our RCT
was evaluating the effect of an educational intervention
to increase chlamydia screening tests in general practices
in England where there is a National screening
programme and where monitoring of testing rates were
routine. Our participants may have been less enthusias-
tic about the design if it had been undertaken in an area
where screening and data monitoring was not routine or
we had been evaluating a more controversial educational
area. It will be important that the nature of the interven-
tion (whether educational, or how accepted), the exact
consent procedure and consent guardian, and data col-
lection are considered when ethics committees approve
such designs so that perceived advantages of such a de-
sign to increase recruitment and reduce bias do not
override the important ethical process and rights of the
trial participants. Furthermore, all participants should be
informed about the design and results as soon as pos-
sible after completion of the intervention evaluation.
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